An international research team has identified a bacterial/viral combination more likely to be present in children with postinfectious hydrocephalus.

BioWorld looks at translational medicine, including: Normal tissue gives clues to bladder cancer’s beginnings.

BioWorld looks at translational medicine, including: Vascular endothelial cells active co-conspirators in metastasis; Targeted delivery improves checkpoint blockade.

BioWorld looks at translational medicine, including: Myelin regulatory factor helps out pancreatic cancer cells.

Researchers at the University of Virginia have used a retrospective database analysis to show that the use of nucleoside reverse transcriptase inhibitors for the treatment of HIV or hepatitis B reduced the risk of developing type 2 diabetes by 33%.

BioWorld looks at translational medicine, including: Buyer beware for SARS-CoV-2 antibody detection; Statins help pancreatic tumors go from bad to worse.

BioWorld looks at translational medicine, including: Breathing new life into obsolete antibiotics.

BioWorld looks at translational medicine, including: Epigenetic resistance to PARP inhibitors; Arthritis is different disease with antibodies than without.

LONDON - Scenic Biotech BV has signed up Genentech as first partner for its high-throughput platform for identifying genetic modifiers that can suppress or even completely block the effect of a disease-causing mutated gene, as starting points for drug discovery and development. Under the terms of the agreement, Scenic will identify modifiers in undisclosed therapeutic areas, with Genentech, part of the Roche Group, having an option to take multiple targets into development.